Comparative Outcomes of Migraine Preventives and Anti-CGRP Therapies for Tinnitus in Patients With Migraine: A Randomized Active-Comparator Controlled Trial (COMPACT-PM)

Many people with migraine also experience tinnitus - a persistent ringing, buzzing, or hissing in the ears - and research suggests these conditions share underlying biological mechanisms, including a protein called calcitonin gene-related peptide (CGRP) that is active in both the brain and the inner ear. COMPACT-PM is a randomized trial comparing two classes of migraine preventive medications in adults with bothersome tinnitus and a history of migraine: anti-CGRP therapies (newer injectable or oral agents that block CGRP or its receptor) versus conventional migraine preventives (antidepressants including amitriptyline, nortriptyline, and venlafaxine; antihypertensives including propranolol, verapamil, and candesartan; and the anticonvulsant topiramate). Participants are randomly assigned - like a coin flip - to one of the two treatment groups; neither group receives a placebo, as both receive active migraine treatment. The study's primary outcome is change in the Tinnitus Functional Index (TFI) over 24 weeks, with additional measures including hearing tests, balance assessments, auditory brainstem response testing, and a comprehensive symptom diary. The study is conducted at the Stanford Ear Institute and is funded by a philanthropic gift to the Department of Otolaryngology - Head & Neck Surgery at Stanford University.

Start Date01 Jul 2026

Sponsor / Collaborator

Stanford University

CTIS2024-517981-40-00

/ RecruitingPhase 3IIT

A randomized placebo-controlled double-blind phase III two-arm study to investigate the reduction of Monthly Migraine Days (MMDs) over 12 weeks of treatment with combination of CGRP mAbs and onabotulinumtoxin A intramuscularly compared with CGRP mAbs and placebo in male and female participants with chronic migraine aged 18-70 years.

Start Date06 Jun 2025

Sponsor / Collaborator-

NCT06237062

/ TerminatedNot Applicable

Real-world Experience of Patients Newly Started on Erenumab in the Gulf Region: a Longitudinal Prospective Observational Study

The objective of this study was to evaluate the effect of erenumab on medication-specific treatment satisfaction in patients who newly started on erenumab over 12 weeks

Start Date05 Jun 2024

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

100 Clinical Results associated with Erenumab (Genetical Recombination)

100 Translational Medicine associated with Erenumab (Genetical Recombination)

100 Patents (Medical) associated with Erenumab (Genetical Recombination)

639

Literatures (Medical) associated with Erenumab (Genetical Recombination)

09 Jun 2026·NEUROLOGY

Glaucoma Risk Associated With Calcitonin Gene–Related Peptide Inhibitor Use in Migraine

Article

Author: Wu, Jr-Wei ; Weng, Chien-Hsiang ; Wang, I-Jong ; Lin, Hui-Ju ; Pan, Ssu-Yu ; Chou, Chien-Chih

BACKGROUND AND OBJECTIVES:

Migraine has been linked to an increased risk of glaucoma, and our study aims to assess the temporal association between calcitonin gene-related peptide inhibitors (CGRPi) and the risks of glaucoma in individuals with migraine.

METHODS:

This multinational retrospective cohort study included adults diagnosed with migraine who received migraine preventive medications in 2018-2024. Participants were categorized into the CGRPi group (erenumab, fremanezumab, galcanezumab, eptinezumab, atogepant, or rimegepant) and non-CGRPi group (valproate, topiramate, flunarizine, candesartan, lisinopril, metoprolol, propranolol, nadolol, amitriptyline, and venlafaxine). Crossovers were not allowed, and the non-CGRPi group included only individuals who never used CGRPi. The CGRPi and non-CGRPi groups were propensity score matched in a 1:1 ratio and were followed for up to 3 years to monitor the occurrence of incident glaucoma. The Cox proportional hazards model was used to compare the risk of glaucoma between CGRPi and non-CGRPi users, with results reported as hazard ratios (HRs) and 95% CIs.

RESULTS:

A total of 73,644 individuals were included in the final analysis. Compared with non-CGRPi users, CGRPi users experience a lower risk of glaucoma development (HR 0.75; 95% CI 0.61-0.92) within 3 years since its first prescription. Individuals using CGRPi also exhibit a reduced risk of glaucoma compared with those using topiramate (HR 0.73; 95% CI 0.59-0.90), valproate (HR 0.54; 95% CI 0.35-0.83), propranolol (HR 0.76; 95% CI 0.59-0.98), metoprolol (HR 0.76; 95% CI 0.59-0.98), lisinopril (HR 0.49; 95% CI 0.38-0.62), amitriptyline (HR 0.69; 95% CI 0.54-0.89), and venlafaxine (HR 0.68; 95% CI 0.50-0.91). In the analysis that further classified participants based on the specific CGRPi used, only users of monoclonal antibody CGRPi show a reduced risk of glaucoma compared with non-CGRPi users (HR 0.77; 95% CI 0.61-0.98). The reduced risk of glaucoma associated with CGRPi is also observed in older adults, women, and those with chronic migraine or migraine without aura.

DISCUSSION:

Among adults with migraine receiving preventive treatment, systemic use of CGRPi, particularly monoclonal antibody CGRPi, is associated with a reduced risk of glaucoma compared with the use of other migraine preventive medications.

CLASSIFICATION OF EVIDENCE:

This is a Class II study demonstrating that CGRPi users with migraine have a lower risk of incident glaucoma when compared with non-CGRPi users with migraine.

01 Jun 2026·HEADACHE

Arterial hypertension: A safety risk of calcitonin gene‐related peptide ligand and receptor blocker class

Article

Author: Croteau, David ; Lee, Paul R. ; Jawidzik, Laura ; Phipps, Christine ; Scripko, Patricia ; Chan, Vicky ; Fitter, Heather D. ; Hughes, Alice ; Tobenkin, Anne ; Brinker, Allen ; Saely, Suprat

Abstract:

Objective:

To identify and analyze adverse event reports of arterial hypertension (hereinafter referred as hypertension ) associated with calcitonin gene‐related peptide (CGRP) ligand (L) and receptor (R) blockers.

Background:

CGRP is a potent peripheral and cerebral vasodilator and plays a key role in the pathogenesis of migraine. The US Food and Drug Administration (FDA) previously identified postmarketing case reports of hypertension associated with erenumab resulting in an amendment of the US Prescribing Information. However, at that time, no hypertension safety signal was apparent for other CGRP‐L/R blockers.

Methods:

In this retrospective pharmacovigilance case series, we reviewed case reports from the FDA Adverse Event Reporting System database and the medical literature through October 15, 2025, for hypertension associated with the use of any of the eight CGRP‐L/R blockers approved and marketed in the United States, except for erenumab. A case of hypertension was defined as (1) the initiation of a pharmacological intervention or emergency department visit or hospitalization for emergent de novo or worsening of preexisting hypertension, OR (2) blood pressure (BP) measurement ≥140 mmHg systolic or ≥90 mmHg diastolic with or without baseline BP measurement reported.

Results:

We identified a total of 106 cases of hypertension in FDA Adverse Event Reporting System and the medical literature with a probable or possible causal association with CGRP‐L/R blocker use: 78 (74%) cases with CGRP‐L monoclonal antibodies and 28 (26%) cases with the CGRP‐R small molecules. Reporting of de novo hypertension was slightly more frequent than worsening of preexisting hypertension. The latency between CGRP‐L/R blocker initiation and hypertension onset was ≤30 days in two‐thirds of the cases. In over one‐third (40/106) of the cases, new antihypertensive treatment was initiated, or the dosage of preexisting antihypertensive treatment was increased. CGRP‐L/R blocker discontinuation occurred in 76% (47/62) of the cases.

Conclusion:

Adverse event case reports provide reasonable evidence of a causal association between hypertension and CGRP‐L/R blockers used for the preventive or acute treatment of migraine. In light of these findings, the US Prescribing Information of the entire CGRP‐L/R blocker class now includes a description of the risk of hypertension in the Warnings and Precautions section.

01 Jun 2026·SLEEP MEDICINE REVIEWS

Sleep and anti-calcitonin gene related peptide (CGRP) drugs: current evidence and perspectives

Review

Author: Romozzi, Marina ; Boccalini, Alberto ; Vernieri, Fabrizio ; Geppetti, Pierangelo ; Sebastianelli, Gabriele ; Ray, Sucharita ; Vigani, Giulia ; Altamura, Claudia ; Iannone, Luigi Francesco ; Viticchi, Giovanna

Migraine and sleep share a bidirectional relationship: sleep disruption can trigger migraine attacks, while migraine impairs sleep continuity and quality. Calcitonin gene-related peptide (CGRP), central to migraine pathophysiology, also contributes to sleep regulation through hypothalamic and brainstem circuits that control arousal and circadian rhythms. This overlap raises the question of whether pharmacological inhibition of CGRP with monoclonal antibodies (mAbs) or gepants could affect sleep. This scoping review summarizes evidence on anti-CGRP therapies and their impact on sleep quality, efficacy, and tolerability. Although results are inconsistent across instruments, emerging data suggest that anti-CGRP mAbs and gepants, particularly erenumab, galcanezumab, and atogepant, can improve subjective sleep quality and objective measures such as sleep efficiency in some cases. Evidence for fremanezumab and eptinezumab remains scarce, whereas large-scale pharmacovigilance datasets indicate low rates of insomnia, somnolence, or abnormal dreams. Overall, current findings suggest that CGRP inhibition impacts the sleep system, but the mechanisms of this interaction remain partly understood, representing a promising area for mechanistic exploration and clinical application. Future studies with standardized sleep endpoints are needed to distinguish direct neuropharmacological effects from indirect benefits mediated by improvement in migraine burden.

News (Medical) associated with Erenumab (Genetical Recombination)

17 Jun 2026

·firstwordpharma.com

Vedana debuts with $46M and a team of veterans to become 'the migraine company'

While the approval of the first CGRP inhibitor in 2018 was a watershed moment for the migraine disease space, too many patients still have too many migraines, Vedana Therapeutics CEO Anurag Agarwal told FirstWord. The biotech, which launched on Wednesday with $46 million in series A funding, is led by experts who helped usher in the first migraine revolution — but recognise that more work is needed. CGRP inhibitors "were the first specialised treatments designed for migraine patients," Agarwal said. "However, two-thirds of patients don't have sufficient benefits, they don't have deep reductions in migraine days" after trying therapies like Amgen's Aimovig (erenumab-aooe) or Teva's Ajovy (fremanezumab-vfrm). To help non-responders get migraine relief, Vedana is developing antibodies that inhibit a wholly independent pathway involving pituitary adenylate cyclase-activating polypeptide (PACAP). "PACAPs, like CGRPs, have been shown that when you infuse it in migraine patients, it induces migraine-like headaches. But unlike CGRPs, it induced a much broader symptomology of migraine… [like] facial puffing, neck stiffness," Agarwal said. In early studies, even with complete CGRP blockade, the infusion of PACAPs still drove migraines, demonstrating that it is a "complementary pathway that could address what is not being addressed by CGRPs today," he added. The company's two lead programmes are a next-generation anti-PACAP mAb and a dual-targeting PACAP/CGRP bispecific antibody. With Wednesday's funding, co-led by Westlake BioPartners and Canaan Partners, Vedana hopes to move both into the clinic next year.Migraine competitionThe biotech is not alone in its pursuit of PACAP inhibition, however. Lundbeck looks to be the most advanced with bocunebart, a PACAP-targeting mAb that recently met the primary endpoint of a Phase IIb migraine study, though several others, including newly public Mentari Therapeutics and Slate Medicines, have preclinical PACAP assets. Despite the rapidly forming PACAP competition, Agarwal isn't worried, noting that CGRP development was also a crowded field. He also called the early success of Lundbeck's programme "wonderful" for patients. How Vedana will stand out, he said, is with best-in-class treatments that are more potent, long-acting, and can be delivered subcutaneously in a patient's home with an autoinjector. "Our goal is to be able to give medicines that are easily delivered to a large number of patients," Agarwal added.Lending Vedana a hand in meeting that goal is its team of experienced migraine scientists. Leon Garcia, the company's other co-founder and chief scientist, previously led the discovery and development of both anti-CGRP and -PACAP antibodies at Alder BioPharmaceuticals, which was acquired by Lundbeck in 2019 for close to $2 billion. Chief Medical Officer Ernesto Aycardi steered the pivotal and post-marketing studies for Ajovy, and Rob Lenz, executive chairman of the board, helmed Aimovig's development in his past role as Amgen's head of global development. "We have that unique experience of discovering, developing and bringing to patients migraine therapies. We have a team that has done that from the early to the late stages. So I think that we are in a very unique position to lead the field," Aycardi told FirstWord. "This company in the future is going to be the migraine company."

Phase 2AcquisitionDrug ApprovalClinical Result

17 Jun 2026

·allsci.com

Vedana launches with USD 46m via Series A to challenge CGRP monopoly in migraine prevention

Seattle-based Vedana Therapeutics has launched from stealth with a USD 46 million Series A financing round to advance a portfolio of antibody-based therapies targeting clinically validated pathways for migraine prevention. The round was co-led by Westlake BioPartners and Canaan Partners, with participation from Dawn Biopharma and Alexandria Venture Investments. Vedana’s pipeline centers on pituitary adenylate cyclase-activating polypeptide (PACAP) biology. Its lead program is a next-generation anti-PACAP antibody, and its second program is a bispecific antibody targeting both PACAP and calcitonin gene-related peptide (CGRP). PACAP is a neuropeptide that, like CGRP, plays a documented role in migraine physiology. Vedana’s antibodies are designed as long-acting, subcutaneously delivered agents intended for self-injection. CGRP-targeted antibodies — including erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality) — established the first generation of preventive migraine biologics and represented a meaningful clinical advance. However, the company and its investors contend that approximately two-thirds of patients remain inadequately controlled on existing therapies, creating a substantial opportunity for agents targeting complementary biology such as PACAP. Competitors in the emerging PACAP space include Lundbeck, which acquired Alder BioPharmaceuticals — the company where Vedana’s co-founder and chief scientific officer Leon Garcia, Ph.D., previously led anti-CGRP and anti-PACAP antibody discovery — and AbbVie, which has disclosed PACAP-targeting programs. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

AcquisitionIPOGene Therapy

17 Jun 2026

·www.biospace.com

Vedana Therapeutics Launches With $46 Million Series A Financing to Advance Next-Generation Migraine Therapies

Targeting clinically validated pathways to enable patients to achieve freedom from migraine Built by the world’s foremost migraine experts and industry leaders Financing co-led by Westlake BioPartners and Canaan Partners SEATTLE--(BUSINESS WIRE)--Vedana Therapeutics (“Vedana”), a biotechnology company developing next-generation therapies for migraine prevention, today emerged from stealth with $46 million in Series A financing. The financing was co-led by Westlake BioPartners and Canaan Partners, with participation from Dawn Biopharma and Alexandria Venture Investments. Vedana’s executive team, board, and advisors include leaders who discovered and developed multiple migraine therapies, including approved calcitonin gene-related peptide (CGRP) antibodies and the emerging pituitary adenylate cyclase-activating polypeptide (PACAP) drug class. Proceeds from the financing will be used to advance Vedana’s portfolio of internally discovered, potentially best-in-class, subcutaneously delivered antibodies targeting clinically validated pathways for migraine prevention. “First-generation CGRP therapies were a major step forward in the treatment of migraine, but most patients are still not adequately controlled,” said Anurag Agarwal, Ph.D., co-founder and chief executive officer of Vedana. “We are now focused on what comes next — targeting biology beyond CGRP, like PACAP and combinations thereof, to deliver on our vision of migraine freedom for all patients.” Approval of multiple CGRP medicines marked the launch of the first generation of specialized therapies for migraine patients. However, two-thirds of the patients are still unable to gain optimal control of their migraine. PACAP, like CGRP, plays a critical role in migraine physiology and is emerging as a complementary approach to treat patients. Based on such clinically validated biology, Vedana has built a portfolio of internally discovered subcutaneously delivered long-acting antibodies. The company’s lead program is the next-generation anti-PACAP antibody, and its second program targets both PACAP and CGRP. While targeting PACAP alone provides a novel approach beyond currently approved drugs, Vedana’s bispecific antibody targeting both PACAP and CGRP could potentially deliver additional efficacy for patients who do not achieve relief with monotherapies. Co-founder and chief scientific officer Leon Garcia, Ph.D., added, “Vedana was founded by a team that has spent years developing antibody therapies against CGRP and PACAP, giving us deep insight into both the promise and the limitations of existing approaches. Drawing on that experience, we designed the next-generation of highly potent long half-life antibodies, targeting self-injecting options for patients in the convenience of their home.” “Vedana’s team has an unparalleled track record and has executed efficiently in generating multiple molecules with best-in-class potential,” said Mira Chaurushiya, Ph.D., managing director at Westlake BioPartners. “As the migraine market continues to evolve, Vedana’s leadership is well positioned to identify and address patient needs.” “The Vedana team represents the deepest concentration of migraine expertise we have seen. Importantly, they bring together the lived experiences from multiple migraine companies and medicines in large and small biotech. They are focused entirely on what the next generation of medicines needs to deliver for patients. We are proud to back them,” said Julie Grant, general partner at Canaan Partners. Built by the Team Behind Modern Migraine Therapeutics Vedana was built by the world’s leading migraine experts and industry leaders with decades of experience across migraine biology, antibody engineering, clinical development, and commercialization. Vedana’s executive leadership team includes: Anurag Agarwal, Ph.D., co-founder and chief executive officer (CEO) – Brings a decade of experience in investing in early stage life science companies as a venture capitalist at Osage University Partners where he led multiple company creation initiatives. Leon Garcia, Ph.D., co-founder and chief scientific officer – Led the discovery and development of both anti-calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) antibodies at Alder BioPharmaceuticals (acquired by Lundbeck), with more than 30 years of experience in antibody development from discovery through late-stage clinical trials. Ernesto Aycardi, M.D., chief medical officer (CMO) – Brings global experience across all phases of drug development, with deep expertise in neurology, having managed the pivotal and post-marketing studies for AJOVY® (fremanezumab-vfrm). In addition, Vedana is supported by internationally renowned leaders in the migraine field, including: Rob Lenz, M.D., Ph.D., executive chair of Vedana’s board of directors -- Former head of global development at Amgen, where he led the development of Aimovig® (erenumab-aooe). Marcelo Bigal, M.D., Ph.D. , member of Vedana’s board of directors -- Former CMO of Labrys, and head of development at Teva, where he led the development of AJOVY® (fremanezumab-vfrm). Steven James – Former CEO of Labrys Biologics (acquired by Teva for AJOVY®), KAI Pharmaceuticals (acquired by Amgen), and Pionyr Immunotherapeutics (acquired by Gilead Sciences). Messoud Ashina, M.D., Ph.D. – Director of the Migraine Unit at the University of Copenhagen and a leading authority in migraine research. David Dodick, M.D. – Chief science and medical officer at Atria and a globally recognized migraine expert. Andy Russo, Ph.D. – Professor of neurology at the University of Iowa and leading preclinical researcher in CGRP and PACAP biology. Frank Porreca, Ph.D. – Associate department head of pharmacology at the University of Arizona and prominent researcher in preclinical models of pain. About Vedana Therapeutics Vedana Therapeutics is a biotechnology company developing next-generation, preventive therapies for migraine by leveraging pituitary adenylate cyclase-activating polypeptide (PACAP) biology, and highly selective combinatorial targeting of clinically validated pathways. Vedana is led by a team of world-renowned experts in migraine drug development and is advancing a portfolio of antibody-based therapies designed to address the significant unmet need in migraine treatment. Visit for more information. Contacts Media Contact Greig Communications, Inc. Kathy Vincent kathy@greigcommunications.com

Acquisition

100 Deals associated with Erenumab (Genetical Recombination)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Erenumab (Genetical Recombination)	N02CD01	DB14039

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Migraine Disorders	United States	Amgen, Inc.	17 May 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Trigeminal Nerve Diseases	Phase 2	United States	Amgen, Inc.	31 May 2022
Trigeminal Nerve Injuries	Phase 2	United States	Amgen, Inc.	31 May 2022
Temporomandibular Joint Disorders	Phase 2	United States	Amgen, Inc.	15 Nov 2021
Flushing	Phase 2	Denmark	Novartis Pharmaceuticals Corp.	09 Jun 2020
Rosacea	Phase 2	Denmark	Novartis Pharmaceuticals Corp.	09 Jun 2020
Neuralgia	Phase 2	Denmark	Novartis AG	09 Apr 2019
Trigeminal Neuralgia	Phase 2	Denmark	Novartis AG	09 Apr 2019
Headache	Phase 2	Denmark	Novartis AG	05 Apr 2019
Headache	Phase 2	Denmark	Amgen, Inc.	05 Apr 2019
Post-Concussion Syndrome	Phase 2	Denmark	Novartis AG	05 Apr 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04603976 (REFORM, Pubmed \| Eur J Neurol)	Phase 4	Migraine Disorders	582	Erenumab 140 mg	icafaebkib(ynrbnlsqmj) = For HIT-6, optimal thresholds included an 8-point reduction (53% sensitivity, 84% specificity) or a 12% relative reduction (54% sensitivity, 84% specificity). qhybyjjhhj (pokohdkqsw ) View more	Negative	01 Apr 2026
NCT03333109 (EMPOwER, Pubmed \| Neurol Clin Pract)	Phase 3	Migraine Disorders	900	Erenumab 140 mg	zlahswjhck(japslpxjwp) = lwnajirbdu jouwnfrlai (xezadpanzy ) View more	Positive	01 Apr 2026
				Erenumab 70 mg	zlahswjhck(japslpxjwp) = xyafxxkfdn jouwnfrlai (xezadpanzy ) View more
NCT04252742 (EMBRACE, Pubmed \| Headache)	Phase 4	-	510	Erenumab 140 mg	canyhirxct(vxzemepnrp) = Compared with placebo, erenumab significantly reduced migraine functional impact as assessed by the four domains of the Migraine Functional Impact Questionnaire, with a least squares mean (95% CI) difference of −7.36 (−10.80, −3.92) for physical functioning, −7.10 (−10.34, −3.87) for usual activities, −6.82 (−10.37, −3.27) for social functioning, and − 7.05 (−10.76, −3.34) for emotional functioning ( p < 0.001 for all domains). cmnruvjqkq (kakgsnitjp )	Positive	01 Mar 2026
				Placebo
NCT04098250 (CTgov)	Phase 2	Post-Traumatic Headache	6	Erenumab (Erenumab)	fualqrpjaf(zuhfcowuiy) = feqlvqwjfp nqkpummsii (rydoroljxe, 2.8) View more	-	23 Oct 2025
				Placebo (Placebo)	fualqrpjaf(zuhfcowuiy) = ayrkveiawk nqkpummsii (rydoroljxe, 6.0) View more
NCT04884763 (CTgov)	Phase 2	Temporomandibular Joint Disorders	30	Erenumab-aooe (Arm A)	phyrbgrxuv(rhfmsaytzd) = duakuljypj xyssqqflhr (smqkpjkrze, zfberzemtq - mlbirgkxyv) View more	-	19 Aug 2025
				Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments (Arm B)	phyrbgrxuv(rhfmsaytzd) = jfapwpmfii xyssqqflhr (smqkpjkrze, atlgctmfip - ygfxonyjhb) View more
NCT03971071 (Pubmed \| Eur J Neurol)	Phase 4	Headache Disorders, Secondary	552	Erenumab 70 mg	mvrxwvfhfu(hsqiuobaiv) = No new safety concerns were identified (grade ≥ 3, 35 [6.3%]; serious, 17 [3.1%]; adverse events leading to treatment discontinuation, 5 [0.9%]) rifyxakbeh (pidddgtjck )	Positive	01 Aug 2025
				Erenumab 140 mg
NCT04970355 (CHERUB01, Pubmed \| JAMA Netw Open)	Phase 2	Cluster Headache CGRP	81	Erenumab	dxbceycrlr(slmrfvzlpl) = npowgehenk kjfuspswdr (ebvanuvqzw )	Negative	17 Jun 2025
				Placebo	dxbceycrlr(slmrfvzlpl) = zpyewfwsec kjfuspswdr (ebvanuvqzw )
NCT04674020 \| NCT04603976 (REFORM study, Pubmed \| J Headache Pain)	Phase 4	Migraine Disorders soluble urokinase-plasminogen activator receptor (suPAR)	623	Erenumab 140 mg	adejviadme(hlkywxfwor): P-Value = 0.005	Negative	24 Apr 2025
				erenumab (Healthy Controls)
NCT04084314 (APOLLON, Pubmed \| J Headache Pain) Manual	Phase 4	Migraine Disorders	701	Erenumab 70 mg	vzztjeskvj(eodgmotiav) = 4.1% of total cohort discontinued erenumab treatment during open-label treatment phase. Out of these, 65.5% (N = 19) were considered treatment-related. vpgtyykiea (kldvohjatg )	Positive	25 Sep 2024
				Erenumab 140 mg
NCT04825678 (CTgov)	Phase 4	Migraine Disorders	240	Erenumab (Erenumab QM: Continued SoC)	ihsvstqcfi(nsaluolprt) = peghlgpskf qqoiivubbr (ffexdzqilp, 32.48) View more	-	19 Sep 2024
				Erenumab (Erenumab QM: Discontinued SoC)	ihsvstqcfi(nsaluolprt) = zkkexbazuo qqoiivubbr (ffexdzqilp, 57.66) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis